Skip to main content

Mucosal abnormalities as key predictive factors of colorectal cancer in ulcerative colitis

In brief

Adenomas in ulcerative colitis mark nearly 10-fold higher colorectal cancer rate

In a Scandinavian population-based study, adenomas in patients with ulcerative colitis were linked to an almost 10-fold higher colorectal cancer rate, and low-grade dysplasia to a more than threefold higher rate. Severe inflammation was not associated with higher risk; the findings challenge current surveillance recommendations, but do not establish which screening approach would be safer or more effective.

Journal
Endoscopy (Q1)
Published
9 November 2026
Study design
Cohort / observational study
Evidence level
Level 3, Low (CEBM 3b)
Authors
Amanda Högdén, Vera Perrin, Hans-Olov Adami, Tine Jess, Lone Larsen, Rasmus Hvidbjerg Gantzel, et al.
PMID
43003118
DOI
10.1055/a-2974-2972

Why clinicians should know about it

  • Picked for Gastroenterology (paper of the day, 14 November 2026): UC-associated colorectal cancer risk and endoscopic surveillance

Abstract

BACKGROUND: Although an increased risk of colorectal cancer (CRC) among patients with ulcerative colitis (UC) is well established, the magnitude and determinants of excess risk remain ambiguous. This uncertainty hampers risk stratification and evidence-based endoscopic surveillance. METHODS: We empaneled a population-based cohort of incident UC cases in Scandinavia, achieved a median follow-up of 15.0 years through record linkages, designed a case-cohort study, and undertook standardized data abstraction from hospital records of 566 patients with CRC and 720 patients from a sub-cohort randomly sampled at baseline. We fitted weighted multivariable Cox proportional hazard models to estimate hazard ratios (HRs) with 95%CIs, which approximates analyzing the full cohort of 90 780 subjects. RESULTS: We confirmed 2-fold higher CRC risk in patients with pancolitis compared with proctitis (HR 2.3, 95%CI 1.5-3.4). We saw no association between severe macroscopic (HR 1.1, 95%CI 0.7-1.8) or microscopic (HR 1.5, 95%CI 1.0-2.3) inflammation and CRC risk. In contrast, low grade dysplasia predicted a more than 3-fold, and adenomas an almost 10-fold excess rate of CRC (HR 9.8, 95%CI 5.2-18.6). Overall, HRs did not depend on follow-up time (0-1 years, 1-8 years, and >8 years). Pharmacologic treatments with biologic drugs (HR 2.4, 95%CI 0.7-7.7) or immunomodulators (HR 1.1, 95%CI 0.7-1.7) did not significantly reduce the CRC rate. CONCLUSIONS: In patients with UC, mucosal abnormalities rather than disease extent and inflammation were the strongest predictive factors of CRC. Our findings do not support prevailing recommendations for endoscopic surveillance.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.